Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

COX-2 mediates tumor-stromal Prolactin signaling to initiate tumorigenesis [CE1-4]

ABSTRACT: COX-2 mediates tumor-stromal Prolactin signaling to initiate tumorigenesis [CE1-4]

PROVIDER: PRJNA521170 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR8539680_1.fastq.gz	Fastqsanger.gz
	SRR8539680_2.fastq.gz	Fastqsanger.gz
	SRR8539681_1.fastq.gz	Fastqsanger.gz
	SRR8539681_2.fastq.gz	Fastqsanger.gz
	SRR8539682_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

COX-2 mediates tumor-stromal Prolactin signaling to initiate tumorigenesis

Project description:COX-2 mediates tumor-stromal Prolactin signaling to initiate tumorigenesis

| PRJNA379327 | ENA

COX-2 mediates tumor-stromal Prolactin signaling to initiate tumorigenesis [DF]

Project description:COX-2 mediates tumor-stromal Prolactin signaling to initiate tumorigenesis [DF]

| PRJNA521167 | ENA

COX-2 mediates tumor-stromal Prolactin signaling to initiate tumorigenesis [DF]

Project description:Tumor-stromal communication within the microenvironment contributes to initiation of metastasis and may present a therapeutic opportunity. Using serial single cell RNA-sequencing in an orthotopic mouse prostate cancer model, we find upregulation of Prolactin receptor as cancer cells that have disseminated to the lung expand into micrometastases. Secretion of the ligand Prolactin by adjacent lung stromal cells is induced by tumor cell production of the COX-2 synthetic product prostaglandin E-2 (PGE-2). PGE-2 treatment of fibroblasts activates the nuclear orphan receptor NR4A (Nur77), with Prolactin as a major transcriptional target for the NR4A-Retinoid X receptor (RXR) heterodimer. Ectopic expression of Prolactin receptor in mouse cancer cells enhances micrometastasis, while treatment with the COX-2 inhibitor Celecoxib abrogates Prolactin secretion by fibroblasts and reduces tumor initiation. Across multiple human cancers, COX-2, Prolactin, and Prolactin receptor show consistent differential expression in tumor and stromal compartments. Such paracrine crosstalk may thus contribute to the documented efficacy of COX-2 inhibitors in cancer suppression.

2019-02-25 | GSE126158 | GEO

COX-2 mediates tumor-stromal Prolactin signaling to initiate tumorigenesis [ChIP-seq]

2019-03-11 | GSE128119 | GEO

COX-2 mediates tumor-stromal Prolactin signaling to initiate tumorigenesis [CE1-4]

2019-02-25 | GSE126159 | GEO

COX-2 mediates tumor-stromal Prolactin signaling to initiate tumorigenesis [cell lines]

2019-02-25 | GSE96675 | GEO

COX-2 mediates tumor-stromal Prolactin signaling to initiate tumorigenesis [single cells]

2019-02-25 | GSE96674 | GEO

COX-2 mediates tumor-stromal Prolactin signaling to initiate tumorigenesis [ChIP-seq]

Project description:COX-2 mediates tumor-stromal Prolactin signaling to initiate tumorigenesis [ChIP-seq]

| PRJNA526491 | ENA

COX-2 mediates tumor-stromal prolactin signaling to initiate tumorigenesis.

Project description:Tumor-stromal communication within the microenvironment contributes to initiation of metastasis and may present a therapeutic opportunity. Using serial single-cell RNA sequencing in an orthotopic mouse prostate cancer model, we find up-regulation of prolactin receptor as cancer cells that have disseminated to the lungs expand into micrometastases. Secretion of the ligand prolactin by adjacent lung stromal cells is induced by tumor cell production of the COX-2 synthetic product prostaglandin E2 (PGE2). PGE2 treatment of fibroblasts activates the orphan nuclear receptor NR4A (Nur77), with prolactin as a major transcriptional target for the NR4A-retinoid X receptor (RXR) heterodimer. Ectopic expression of prolactin receptor in mouse cancer cells enhances micrometastasis, while treatment with the COX-2 inhibitor celecoxib abrogates prolactin secretion by fibroblasts and reduces tumor initiation. Across multiple human cancers, COX-2, prolactin, and prolactin receptor show consistent differential expression in tumor and stromal compartments. Such paracrine cross-talk may thus contribute to the documented efficacy of COX-2 inhibitors in cancer suppression.

| S-EPMC6431196 | biostudies-literature

COX-2 mediates tumor-stromal Prolactin signaling to initiate tumorigenesis

Project description:This SuperSeries is composed of the SubSeries listed below.

2019-02-25 | GSE96676 | GEO